Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor. As a result of concerns for potential infusion-related hypersensitivity reactions (HSRs), initial phase ...
Exploring shorter infusion durations for the full 450 mg BRIUMVI infusions Data continue to support that 450 mg of BRIUMVI may be safely administered in 1 hour as an initial infusion for participants ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback